Cyclosporine Drugs Global Market Report 2025

The cyclosporine drugs market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historic period can be attributed to several factors, including the rising geriatric population, the increasing use of cyclosporine in ophthalmic treatments, a growing number of clinical trials for cyclosporine-based drugs, increased government support for drug research and development, and a surge in healthcare spending.

The cyclosporine drugs market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth projected during the forecast period can be attributed to several factors, including the increasing prevalence of autoimmune diseases, a rise in organ transplant cases, a growing number of patients with dry eye disease, heightened awareness of cyclosporine treatments, and expanding healthcare infrastructure. Key trends expected in the forecast period include advancements in drug delivery systems, improved formulations for cyclosporine drugs, innovation in non-preserved formulations for eye drops, the development of generic cyclosporine drugs, and the adoption of cyclosporine in veterinary medicine.

The growing demand for organ transplantation is expected to drive the expansion of the cyclosporine drugs market. Organ transplantation involves replacing a damaged or failing organ in a person’s body with a healthy one from another individual. The rise in organ transplants is largely due to the increasing prevalence of end-stage organ diseases, with advancements in medical diagnostics and treatments extending patient lifespans, allowing more individuals to live long enough to require organ replacements. Cyclosporine drugs play a critical role in organ transplantation by suppressing the immune system's natural response to reject foreign tissues, helping to prevent the transplanted organ from being attacked and damaged by the recipient’s immune cells. For example, in December 2024, the Australian Institute of Health and Welfare reported that 938 kidney transplants were performed in Australia in 2022, with 90% being first-time kidney transplants. Among these, 76% came from deceased donors, while 24% were from living donors. As such, the increasing demand for organ transplants is driving the growth of the cyclosporine drugs market.

Leading companies in the cyclosporine drugs market are focusing on developing advanced ophthalmic solutions to deliver targeted treatment directly to the eyes. Ophthalmic medications are specially formulated to treat eye conditions such as infections, inflammation, and dry eye, and are typically available in the form of drops, ointments, or gels. For example, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for VEVYE, the first water-free and preservative-free 0.1% cyclosporine ophthalmic solution. Developed using Novaliq’s proprietary EyeSol technology, VEVYE provides an innovative treatment for dry eye disease, demonstrating significant effectiveness within just four weeks. Its unique water-free formulation enhances drug stability, improves patient comfort, and minimizes irritation. This approval represents a major step forward in ophthalmic drug delivery, offering more precise targeting of inflammation in the eyes.

In October 2024, Novaliq GmbH, a Germany-based manufacturer of cyclosporine drugs, entered into a partnership with Laboratoires Théa to launch a ciclosporin eye drop solution in Europe as well as select Middle Eastern and North African (MENA) regions. This collaboration highlights a shared commitment to providing innovative treatments for patients suffering from dry eye disease. The upcoming introduction of Vevizye, a non-preserved cyclosporine eye drop solution, will expand the range of non-preserved treatments available for dry eye relief. Dry eye is a condition that significantly impacts the quality of life for many individuals, and this new treatment aims to offer a highly effective option. Laboratoires Théa is a France-based company that brings its expertise to the partnership, further strengthening the initiative.

Major players in the cyclosporine drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Astellas Pharma Inc., Apotex Inc., Dr. Reddy’s Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Biocon Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Concord Biotech Limited, CKD Bio Corporation, ChemWerth Inc., Strides Pharma Science Limited, and Fishfa Biogenics.

North America was the largest region in the cyclosporine drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cyclosporine drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cyclosporine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cyclosporine drugs are a class of immunosuppressive medications primarily used to prevent organ rejection following transplants and to treat various autoimmune disorders. These medications work by inhibiting the activity of T-lymphocytes, a type of white blood cell involved in the immune response, thereby reducing inflammation and immune system overactivity.

Cyclosporine drugs come in two main types oral and parenteral. Oral cyclosporine medications are taken by mouth to suppress immune system activity. They are available in several formulations, including capsules, oral solutions, injectables, and topical treatments. These drugs are used for conditions such as organ transplantation, autoimmune disorders, ophthalmic conditions, and dermatological issues, and are prescribed in various settings, including hospitals, specialty clinics, homecare environments, and pharmaceutical retail outlets.

The cyclosporine drugs market research report is one of a series of new reports that provides cyclosporine drugs market statistics, including cyclosporine drugs industry global market size, regional shares, competitors with a cyclosporine drugs market share, detailed cyclosporine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine drugs industry. This cyclosporine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cyclosporine drugs market consists of sales of therapeutic drug monitoring kits, supportive care medications and cyclosporine active pharmaceutical ingredient. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.